Malignant Tumor Chemotherapy In Patients With Peripheral Blood T Lymphocyte Subsets Changes Before And After The Clinical Observation

Background and Objective：Due to incidence and mortality of malignant tumor increasedgradually, which has become one of the problem effects life and health ofhuman. The relevant research has been approved that occurrence anddevelopment of malignant tumor is closely related to cellular immunefunction. Through CD3+CD4+、CD3+CD8+、CD4+／CD8+inspection ofperipheral blood T lymphocyte subsets from before and afterchemotherapy for malignant tumor patient to compare with the levelchanges of CD3+CD4+、CD3+CD8+、CD4+／CD8+between before andafter chemotherapy and observe the relativity between chemotherapycurative effect and CD4+、CD8+、CD4+／CD8+level changes, to discussthe effect of chemotherapy on cellular immune function and clinicalsignificance of immunity support treat which could conclude CD3+CD4+、CD3+CD8+cell of T lymphocyte subsets is the main target for cellimmunity function.Methods：88patients with malignant tumor Clinical data collection at Tumourand Hematology Department of Jilin University Bethune Second Hospitalfrom1stDec2013to28thFeb2015.All Patients were confirmed byhistopathological diagnosis and together with relevant assist inspection ofimaging, serum tumor markers,ultrasound and so on. Base on theclassification of disease description and illness to process chemotherapyand immunity treatment according to standard scheme. Patient information (observation group): male32cases, female56cases, age ranged from30-75years old, the median age is59years old. Lung cancer21cases (6patients with small cell lung cancer,15patients with non-small cell lungcancer,),20patients with digestive system tumors (7cases with gastriccancer,5cases with colorectal cancer,8cases with colon cancer),13caseswith breast cancer,22cases with ovarian cancer,12cases with kidneycancer. The Lung cancer group is divided into9cases with chemotherapygroup (CR+PR+SD) and12cases with not alleviate chemotherapy group(PD) according to curative effect. Comparison Group: Selected62healthblood samples from physical examination center of our hospital, age rangefrom25-78, median age is58years old, including male34cases, female28cases. All patients from Comparison Group not receive immunityrestrain drug and medicine which could affect immunity function recently,without internal medicine e.g.: autoimmune disease, diabetes mellitus,thyroid disease and so on which could affect immunity function.To inspect CD3+CD4+、CD3+CD8+、CD4+／CD8+quantity and ratioof Peripheral blood T lymphocyte subsets from patients of observationgroup and Comparison Group by flow cell examination technology;Inspect tumour marker (CA125) of ovarian cancer by tumour markerbiochip examination technology. To estimate curative effect of remission（CR+PR+SD）and non-remission（PD）Lung cancer patients by Lung CTimage results after chemotherapy.All data processed by SPSS190statistical software, calculatedinformation indicated through means standard deviation(±), adopt “t” testto compare with difference of each group. P <0.05indicated thedifference has statistical significance.Results: 1. Compare T lymphocyte subsets CD3+CD4+, CD3+CD8+testresults of88malignant tumor patients before chemotherapy and62healthy people, CD3+CD4+level of malignant tumor patients islower than healthy people, while its CD3+CD8+level is higher thanhealthy people, but P value is over0.05, the difference has nostatistical significance; CD4+/CD8+level of malignant tumor patientsis significantly higher than healthy people, P<0.05, the difference hasstatistical significance.2. T lymphocyte subsets CD3+CD4+, CD4+/CD8+level of21lungcancer patients is a little bit higher after chemotherapy, while CD3+CD8+level is a little bit lower after chemotherapy, but P>0.05, thedifference has no statistical significance. T lymphocyte subsets CD3+CD4+, CD4+/CD8+level of9lung cancer patients who relieved alittle after chemotherapy is significantly higher after chemotherapy,CD3+CD8+level is significantly lower after chemotherapy, thedifference has statistical significance,(P<0.05). CD3+CD4+,CD4+/CD8+level of12lung cancer patients who are not relieved afterchemotherapy is still low after chemotherapy, CD3+CD8+level isstill high, which has no statistical significance, the difference is notsignificant,(P>0.05).3. The difference of T lymphocyte subsets CD3+CD4+, CD3+/CD8+and CD4+/CD8+level of ovarian cancer patients before and afterchemotherapy has no statistical significance (P>0.05). But CA125level of ovarian cancer patients after chemotherapy is significantlylower, P<0.05, the difference has statistical significance.4. T lymphocyte subsets CD3+CD4+, CD3+/CD8+and CD4+/CD8+level of breast cancer patients is high after chemotherapy, especiallyfor CD3+CD4+, but the difference has no statistical significance(P>0.05). 5. T lymphocyte subsets CD3+CD4+, CD3+/CD8+and CD4+/CD8+level of digestive system malignant tumor patients has no significantdifference before and after chemotherapy, P>0.05, the difference hasno statistical significance.6. CD3+CD4+, CD4+/CD8+of kidney malignant tumor patients issignificantly higher after immunotherapy, CD3+CD8+level issignificantly lower, P<0.05, the difference has statistical significance.Conclusions:1. compared with healthy people, malignant tumor patient has lower cellimmune function;2. chemotherapy will not damage malignant tumor patient’s cell immunefunction;3. Immunotherapy will improve malignant tumor patient’s cell immunefunction.